{"id":"W4411084855","doi":"10.1200/jco-25-00166","title":"Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Bendamustine; Idelalisib; Medicine; Chronic lymphocytic leukemia; Rituximab; Internal medicine; Ofatumumab; Gastroenterology; Clinical endpoint; Hazard ratio; Venetoclax; Ibrutinib; Leukemia; Lymphoma; Oncology; Confidence interval; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008820469,0.0009136497,0.006940448,0.001727615,0.0001479465,0.00005894282,0.001212552,0.001990578,0.0004852526],"category_scores_gemma":[0.02190553,0.00071777,0.001756196,0.002432831,0.00151836,0.0003476103,0.0006163743,0.001853065,0.00008213791],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.1980456,"about_ca_system_score_gemma":0.3563892,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00269946,"about_ca_topic_score_gemma":0.001159178,"domain_scores_codex":[0.9829709,0.001614936,0.01069976,0.001192529,0.001890924,0.001630936],"domain_scores_gemma":[0.9804209,0.01104433,0.004146958,0.001412375,0.001783466,0.001191909],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8215061,0.01816492,0.0001238194,0.001060463,0.001603648,0.01132087,0.0001740929,0.0006896382,0.00170528,0.0002545003,0.00591751,0.1374792],"study_design_scores_gemma":[0.8736801,0.07154769,0.0002440545,0.002421117,0.001844391,0.001284538,0.0002542214,0.02691108,0.006778179,0.0001110561,0.01442022,0.0005033787],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9829336,0.004017566,0.0001940801,0.00103989,0.006320514,0.002185841,0.00004750676,0.00008173502,0.003179202],"genre_scores_gemma":[0.9894745,0.003810346,0.001087931,0.0008538134,0.002776886,0.00006927167,0.00005736695,0.0001190649,0.001750802],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1583436,"threshold_uncertainty_score":0.9995273,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1296546004483546,"score_gpt":0.4747918773236469,"score_spread":0.3451372768752924,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}